Micron rides memory price spike into earnings with stock up 62%, drubbing its tech peers
Sanjay Mehrotra, president and chief executive officer of Micron Technology Inc., during a groundbreaking ceremony for the new Micron Technology
Read More
price
We’re raising our Costco price target after a good but not great quarter. Here’s why
Costco Wholesale reported solid quarterly results on Thursday, slightly beating analyst forecasts on the key lines. While we would have
Read More
We’re boosting our price target on retail stock TJX after another knockout quarter
Shares of TJX Companies were flat on Wednesday despite the off-price retailer delivering another fantastic quarterly report. Conservative guidance, while
Read More
As Trump declares inflation tamed, Iran conflict threatens new price pressures
Gas prices at a Sunoco gas station in Media, Pennsylvania, US, on Monday, March 2, 2026. Oil surged the most
Read More
We cut our Palo Alto price target, but view the post-earnings drop as an opportunity
Palo Alto Networks on Tuesday evening delivered a strong quarter. But in a market with no room for error, the
Read More
In bitcoin price plummet, ETF flows are down but aren’t signaling ‘crypto winter’ investor
Bitcoin’s massive slump from a record price above $126,000 last October has darkened sentiment across the crypto landscape. Faith has
Read More
Our DuPont thesis is working according to plan. We’re raising our price target
A newly slimmed-down DuPont reported strong quarterly results on Tuesday, sending its stock to a new all-time high. Our long-running
Read More
BP suspends share buyback plan in fresh sign of oil price pressure
Trowbridge in Somerset, England, on March 15, 2025. Anna Barclay | Getty Images News | Getty Images British oil giant
Read More
We’re increasing our price target on Bristol Myers after earnings and guidance top forecasts
Bristol Myers Squibb on Thursday delivered strong fourth quarter results — and better yet, issued a 2026 forecast that was
Read More
We’re raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat
Eli Lilly ‘s fourth-quarter results blew past Wall Street estimates on Wednesday, as key GLP-1 drugs, Mounjaro for diabetes and
Read More